Search company, investor...
Acarix company logo


Founded Year



Corporate Minority | Alive

Total Raised


About Acarix

Acarix has developed the CADScor System for early diagnosis of Coronary Artery Disease (CAD), which is based on recording of acoustic murmurs in the heart, caused by narrowed coronary arteries. The size of the device is equivalent to a cell phone and it is attached to the chest of the patient via a specially developed patch.

Headquarters Location

Diplomvej 378

Kongens Lyngby, DK-2800,


(+45) 5362 1481

Missing: Acarix's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Acarix's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Acarix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Acarix is included in 3 Expert Collections, including Medical Devices.


Medical Devices

11,945 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health Monitoring & Diagnostics

3,087 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Health IT

7,901 items

Acarix Patents

Acarix has filed 12 patents.

The 3 most popular patent topics include:

  • Cardiac anatomy
  • Cardiac arrhythmia
  • Cardiac procedures
patents chart

Application Date

Grant Date


Related Topics




Cardiac arrhythmia, Cardiology, Cardiac anatomy, Cardiovascular physiology, Heart diseases


Application Date


Grant Date



Related Topics

Cardiac arrhythmia, Cardiology, Cardiac anatomy, Cardiovascular physiology, Heart diseases



Latest Acarix News

Study published in Heart strengthens diagnostic value of Acarix CADScor System

Mar 14, 2023

News Provided By Share This Article Acarix, a leader in acoustic and AI-based cardiac diagnostics Acarix, today announced the release of a new study published in the March 2023 issue of the scientific journal Heart. NEW YORK, NEW YORK, UNITED STATES, March 14, 2023 / / -- Acarix , a leader in acoustic and AI-based cardiac diagnostics, today announced the release of a new study published in the March 2023 issue of the scientific journal Heart. The study confirms that the CADScor ®System has a very high rule-out accuracy in low-risk patients with chest pains, and potential to reduce the need for further, unnecessary clinical testing in this patient group by almost 50%. The clinical study, published in Heart by Rasmussen et al, investigated the diagnostic performance of the Acarix CADScor System on 1,683 patients seeking healthcare for stable chest pain symptoms, and that were referred on for coronary CT angiography. The study also evaluated the potential of the CADScor System to reduce the proportion of low-risk patients undergoing unnecessary cardiac assessments based on ESC-PTP guidelines alone. The study concluded that the CADScor System had a very high rule-out accuracy of coronary artery disease (CAD) in the patient cohort. Furthermore, the study showed that nearly half of all grey zone patients (with low-probability of CAD with ESC-PTP 5% to ≤15%) could be reclassified to be assessed with the CADScor System, showing a clear potential to help avoid further unnecessary clinical testing in larger patient groups. “This is yet another very important study for Acarix that validates our AI-based technology and demonstrates the value that CADScor System brings to healthcare providers and patients. The ability to re-classify patients into a lower risk group is clinically relevant and an important driver for increased utilization of the CADScor System leading to faster patient evaluations, avoidance of unnecessary tests, and reduced overall diagnostics costs”, comments Helen Ljungdahl Round, Acarix President & CEO. “When using traditional clinical likelihood models, such as the ESC-PTP, the low likelihood patient group can be clinically challenging, both from a patient volume perspective and from a clinical decision-making perspective,” commented Samuel Emil Schmidt, Associate Professor, Acarix co-founder, and study co-author. “Importantly, this study shows the results of using the CADScor System, to drive clarity in the large middle group (5% to ≤15% ESC-PTP), where the question is whether the patient should be sent home or be referred for further testing. For more information contact: Christian Lindholm, CFO, phone +46 705 118333, email About Acarix Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, is Certified Advisor of Acarix. For more information, please visit .

Acarix Frequently Asked Questions (FAQ)

  • When was Acarix founded?

    Acarix was founded in 2004.

  • Where is Acarix's headquarters?

    Acarix's headquarters is located at Diplomvej 378, Kongens Lyngby.

  • What is Acarix's latest funding round?

    Acarix's latest funding round is Corporate Minority.

  • How much did Acarix raise?

    Acarix raised a total of $4.7M.

  • Who are the investors of Acarix?

    Investors of Acarix include Puhua Jingxin Guzhou Health Management, SEED Capital, Seventure Partners and Sunstone Capital.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.